Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165256 · ClinicalTrials.gov registry record · Phase 2
Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast
A Phase 2 study of Ductal Carcinoma in Situ of the Breast, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 158
- Enrollment target
- 2
- Study locations
NCT00165256: Active Phase 2 study of Ductal Carcinoma in Situ of the Breast, sponsored by Dana-Farber Cancer Institute.
NCT00165256 is a Phase 2 study of Ductal Carcinoma in Situ of the Breast that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 158 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00165256, a Phase 2 study of Ductal Carcinoma in Situ of the Breast, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 158 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine if wide excision (surgical removal) alone is adequate treatment for small, grade 1 or 2 ductal carcinoma in situ (DCIS) of the breast.
Primary Outcome
Using information gathered from follow-up physical examinations and mammography to check for recurrence (DCIS or invasive carcinoma in the breast), DCIS patients treated with wide excision alone will be evaluated.
Conditions Studied
Interventions
- OTHER Observation
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 1995-05 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What the registry record for NCT00165256 still lists
NCT00165256 is an interventional study that assigns participants to a tested intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (19% higher).
The record links to 1 condition, with Ductal Carcinoma in Situ of the Breast appearing as the primary indexed condition, and to 1 intervention - of which Observation is the first listed.
NCT00165256 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00165256 about?
NCT00165256 is a clinical study titled "Wide Excision Alone as Treatment for Ductal Carcinoma in Situ of The Breast". The purpose of this study is to determine if wide excision (surgical removal) alone is adequate treatment for small, grade 1 or 2 ductal carcinoma in situ (DCIS) of the breast.
What is the current status of trial NCT00165256?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 1995-05. Estimated completion is 2027-12.
What conditions does trial NCT00165256 study?
This clinical trial studies the following conditions: Ductal Carcinoma in Situ of the Breast.
What interventions are being tested in trial NCT00165256?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT00165256?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00165256 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00165256's enrollment target sits among peer trials
158 443rd of 2000 higher than 1,558 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia